Test-negative design assessed KP.2 vaccine effectiveness, showing significant protection against COVID-19 in vaccinated individuals.
Between November 2024 and April 2025, the Canadian Sentinel Practitioner Surveillance Network assessed KP.2 vaccine effectiveness against outpatient COVID-19 by test-negative design. Vaccination protected best during the first two months, reducing risk by two-thirds among vaccinated versus unvaccinated individuals, declining by 3-4 months, and reducing the risk overall by half.
No takes yet. Share an insight, caveat, or question.
Separovic et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: